Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis.

ABSTRACT: Patients with interstitial lung disease can develop a progressive fibrosing phenotype characterised by an irreversible, progressive decline in lung function despite treatment. Current therapies slow, but do not reverse or stop, disease progression and are associated with side-effects that can cause treatment delay or discontinuation. Most crucially, mortality remains high. There is an unmet need for more efficacious and better-tolerated and -targeted treatments for pulmonary fibrosis. Pan-phosphodiesterase 4 (PDE4) inhibitors have been investigated in respiratory conditions. However, the use of oral inhibitors can be complicated due to class-related systemic adverse events, including diarrhoea and headaches. The PDE4B subtype, which has an important role in inflammation and fibrosis, has b

SUBMITTER: Kolb M 

PROVIDER: S-EPMC9949383 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature